List of Xifaxan drug patents
Xifaxan is owned by Salix Pharms.
Xifaxan contains Rifaximin.
Xifaxan has a total of 27 drug patents out of which 0 drug patents have expired.
Xifaxan was authorised for market use on 25 May, 2004.
Xifaxan is available in tablet;oral dosage forms.
Xifaxan can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof, treatment of patients with hepatic encephalopathy (he), method of treating travelers' diarrhea, reduction in risk of overt hepatic encephalopathy (he) recurrence, treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults., the treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof., treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults., treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older, reduction in risk of overt hepatic encephalopathy (he) in adults, treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof., reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode.
The generics of Xifaxan are possible to be released after 02 October, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 4 months from now) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(2 years from now) | |
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(2 years from now) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(6 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(6 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(6 years from now) | |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; Reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Reduction in risk of overt hepatic encephalopathy (he) recurrence; Method of treating travelers' diarrhea; Reduction in risk of overt hepatic encephalopathy (he) in adults; Treatment of patients with hepatic encephalopathy (he); The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic